Aripiprazole Tablet
Product Images NDC 87441-006

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 87441-006). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

A (8744100601)

Label for Aripiprazole Tablets USP, 5 mg oral tablets. The label includes the NDC number 87441-006-01, states it is prescription only, and mentions each tablet contains 5 mg Aripiprazole. It also provides storage instructions and notes the package is child-resistant. The label indicates repackaging by Unit Dose Solutions, Inc. and distribution by Tuckahoe Enterprises, LLC.*

FDA Label Image

Figure9 (Aripiprazole Fig9)

A line graph depicting the change in YGTSS total TIC score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, showing a declining trend in scores for Aripiprazole groups compared to placebo.*

FDA Label Image

Figure4 (Aripiprazole Fig4)

A pharmacokinetic chart illustrating fold change and 90% confidence intervals of Aripiprazole across special populations. Variables include CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment, comparing AUC and Cmax changes relative to a reference group.*

FDA Label Image

Figure5 (Aripiprazole Fig5)

A graph showing the fold change in dehydro-aripiprazole pharmacokinetics (AUC and Cmax) with 90% confidence intervals. The variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, each compared to their reference groups.*

FDA Label Image

Figure6 (Aripiprazole Figure6)

A line graph comparing the proportion of relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization (0 to 182) and the y-axis shows the proportion with relapse (0 to 1.0). Two lines depict relapse proportions for Aripiprazole (lower curve) and placebo (higher curve). Below the x-axis, the number of subjects at risk is listed for each group at various days.*

FDA Label Image

Figure7 (Aripiprazole Figure7)

A Kaplan-Meier curve chart depicting the proportion of subjects with relapse over days from randomization for Aripiprazole and placebo groups. The x-axis represents days from randomization (0 to 182), and the y-axis shows the proportion with relapse (0 to 1). The chart includes the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure8 (Aripiprazole Figure8)

A Kaplan-Meier curve depicting the proportion of subjects with relapse over days from randomization comparing Aripiprazole and placebo groups. The graph shows relapse proportions on the vertical axis and days from randomization on the horizontal axis. The number of subjects at risk is tabulated below the graph for both treatment groups at multiple time points.*

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure of aripiprazole, showing its molecular framework with two chlorine atoms, piperazine ring, an ether linkage, and a quinolinone moiety.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A chart displaying the effect of various drugs on the pharmacokinetics of Aripiprazole, showing fold changes in AUC and Cmax with 90% confidence intervals. It compares CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs relative to a reference without interacting drugs.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A chart depicting the effect of various drugs on Aripiprazole pharmacokinetics, showing changes in AUC and Cmax relative to a reference without interacting drugs. The graph includes data for CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam, illustrating fold changes with 90% confidence intervals.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A chart showing the effect of Aripiprazole on other drugs, displaying fold change and 90% confidence intervals for various drugs including dextromethorphan, S-warfarin, R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The horizontal axis measures change relative to reference without interacting drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.